TrialJapanese journal of ophthalmology2016

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.

Ikuko Kachi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.